biOasis Technologies Ord Shs V.BTI.H

MTX110

[prophetoffactz]

BTI's bold move places an important bet on Midatech's lead clinical asset MTX110. If this drug works Biodexa becomes a much stronger company, potentially. The lead trial with MTX110 is for an ultra-rare pediatric cancer.

Looks like some clinical data within about one month:

"In addition, the company expects to report data in the next couple of months from the second Phase I study assessing MTX110 in DIPG, conducted by Columbia University." Edison Group November 15
Midatech Pharma - Patient recruitment begins in rGBM study | Edison (edisongroup.com)

------

"As a reminder, Midatech had earlier (in October 2020) presented interim data from its other UCSF conducted Phase I study, which not only met its primary endpoint in terms of safety but also demonstrated exceptionally positive early efficacy signals, including median overall survival of 26.06 months (CI 11.3–26.06 months) versus 10 months following standard of care radiation therapy." Midatech Pharma - Interim DIPG data to be presented at ISPNO | Edison (edisongroup.com)


Another clinical trial using MTX110 just enrolled its first patient recently and targets glioblastoma which is a $5 billion market. The trial for the ultra-rare pediatric cancer using the same drug and delivery technology would appear to support the glioblastoma trial.

[prophetoffactz]

Looks like some clinical data within about one month against the ultra-rare pediatric brain cancer DIPG. There has already been one phase I trial with 7 patients with remarkable though non-statistically significant results for survival(26 months vs. 10 months). If the results are confirmed in this second study I wonder how strong the read-through is to the glioblastoma trial recently initiated

[MBT123]

Isn't %10 of something better than %100 of nothing? I mean we're close either way but it's painfully obvious for "whatever" reason no pharma or anyone wanted this thing for even coffee change for them..I'll cash out at .25 next month..That maybe high but I feel like it's that or zilch 

[prophetoffactz]

License an early stage asset to pharma and they can want it all too leaving you with a small royalty, etc. We've watched BTI struggle with the licensing model. Pharma also works on their own timeline and can demand secrecy. Midatech appears to like what it sees concerning its assets and wants to escape the early stage licensing model. They want the assets for themselves. When someone wants an

[prophetoffactz]

An early-stage licensing model may be particularly unsustainable in a high inflation environment. No one really cares about revenue 7-10 years out given the inflation rate and the clinical risk and cash burn to get there. You don't make much licensing early to pharma. The burn rate quickly eats it up. 25% of biotech has has traded below the value of cash in recent months. No one cares. BTI